NCT01787799 - EVOLVE II QCA: A Prospective, Multicenter Trial to Assess the SYNERGY Stent System for the Treatment of Atherosclerotic Lesion(s) | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

August 31, 2014

Study Completion Date

October 31, 2014

Conditions

Atherosclerotic Lesion(s)

Interventions

DEVICE

SYNERGY

Synergy is a device/drug combination product composed of two components, a device (coronary stent system including a chromium stent platform) and a drug product (a formulation of everolimus contained in a bioabsorbable polymer coating.

Trial Locations (13)

622

North Shore Hospital, Auckland

1003

Mercy Angiography Unit, Ltd., Auckland

1010

Auckland City Hospital, Auckland

1050

Ascot Angiography Ltd, Auckland

1640

Middlemore Hospital, Auckland

3085

St Vincent's Hospital Melbourne, Fitzroy

3168

Monash Medical Centre-Clayton Campus, Clayton

4032

The Prince Charles Hospital, Chermside

6160

Fremantle Hospital, Fremantle

8011

Christchurch Hospital NZ, Christchurch

119074

National University Hospital, Singapore

168752

National Heart Centre, Singapore

247-8533

Shonan Kamakura General Hospital, Kamakura-shi